Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | RELEVANCE trial analysis: investigating the impact of lymphocyte/monocyte ratio on patient outcomes

Pablo Mozas • 16 Jun 2023
ICML 2023
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide Rituximab
RELEVANCE

Pablo Mozas, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain, discusses the impact of the tumor microenvironment in follicular lymphoma (FL), highlighting the importance of analyzing the lymphocyte-to-monocyte ratio in this disease. Dr Mozas then summarizes the findings from an analysis of the RELEVANCE trial (NCT01650701) which investigated whether the lymphocyte-to-monocyte ratio had an impact on the survival of patients enrolled in this trial. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pablo Mozas

1:49
The importance of better understanding the genomic landscape of follicular lymphoma
Pablo Mozas • 16 Jun 2023
2:26
The value of zanubrutinib in the CLL treatment armamentarium & SEQUOIA trial updates
Pablo Mozas • 16 Jun 2023

Related Videos

2:39
The role of bispecific antibodies in the treatment landscape for R/R DLBCL
Wendy Osborne • 22 Apr 2024
1:24
Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment
Paolo Cortesi • 24 Apr 2024
2:45
The value of axi-cel as a second-line treatment in R/R LBCL
Paolo Cortesi • 24 Apr 2024
5:42
Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD
Nina Worel • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals